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Abstract: Increasing evidence indicates that oxidative damage exists in schizophrenia. Available literature about possible 
mechanisms of oxidative stress induction was reviewed. Furthermore, possibilities of measuring biomarkers of schizo-
phrenia outside the central nervous system compartment, their specificity for different types of schizophrenia and potential 
therapeutic strategies to prevent oxidative injuries in schizophrenia were discussed. Data were extracted from published 
literature found in Medline, Embase, Biosis, Cochrane and Web of Science, together with hand search of references. 
Search terms were: schizophrenia, oxidative stress, antipsychotics, antioxidants and fatty acids. Finding a sensitive,  
specific and non invasive biomarker of schizophrenia, which could be measured in peripheral tissue, still stays an   
important task. Antioxidant enzymes, markers of lipid peroxidation, oxidatively modified proteins and DNA are   
most commonly used. As it considers the supplemental therapy, according to our meta-analysis vitamin E could   
potentially improve tardive dyskinesia, while for the effect of therapy with polyunsaturated fatty acids there is no   
clear evidence. Oxidative stress is a part of the pathology in schizophrenia and appears as a promising field to develop  
new therapeutic strategies. There is a need for well designed, placebo controlled trials with supplementation therapy in 
schizophrenia.  
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INTRODUCTION 
  Schizophrenia is a devastating mental disorder, expressed 
in the form of abnormal mental functions and disturbed be-
havior. It has a life-time prevalence of approximately 1% of 
the world’s population [1]. The disorder has a bad outcome, 
regardless of different treatments (pharmacological, social, 
cognitive etc.). Cardinal symptoms of schizophrenia include 
positive and negative symptoms, and cognitive dysfunction 
and deterioration in social and occupational functioning [2]. 
Schizophrenia is related to different neurodevelopmental, 
structural and behavioral abnormalities. It has been proposed 
that such abnormalities could originate from malfunctioning 
genes and/or non-genetic factors such as ethnicity, drug and 
alcohol abuse, life style, medications, pre-natal and neonatal 
infections, maternal malnutrition, complications during birth 
and many other factors. By inducing cellular metabolic stress 
these factors appear to increase the possibility of oxidative 
stress and damage [3, 4]. Oxidative stress is common to sev-
eral psychiatric disorders [5]. The mechanisms have been 
most widely studied in schizophrenia, employing various 
areas of oxidative research, including oxidative biomarkers 
assays, psychopharmacology, and clinical studies with anti-
oxidants. 
  The scope of this article is to review the available litera-
ture on oxidative status in patients with schizophrenia, in-
cluding reactive oxygen species and reactive nitrogen species 
production, antioxidant defense and influence of antipsy-
chotic treatment. Furthermore, the possibility of measuring  
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biomarkers in different tissues, their specificity for different 
types of schizophrenia, and potential therapeutic strategies to 
prevent reactive species (RS) mediated injuries in patients 
with schizophrenia will be examined. Data was obtained by 
searching the published literature: Medline, Embase, Biosis, 
Cochrane and Web of Science. Search terms were: schizo-
phrenia, oxidative stress, antipsychotics, antioxidants, and 
fatty acids. 
METHODOLOGICAL CONSIDERATIONS 
Oxidative Stress 
  Oxidative stress is defined as a disturbance in the pro-
oxidant/antioxidant balance in favor of the former, leading to 
potential damage. Thus, diminished antioxidants and/or in-
creased production of RS will result in oxidative damage of 
cell lipids, proteins, enzymes, carbohydrates and DNA [6]. A 
growing body of evidence indicates that oxidative damage 
exists in schizophrenia [7-9]. Although this may not be the 
main cause, oxidative damage has been suggested to be a 
common pathogenic process that contributes to declining 
course and poor outcome in schizophrenia [7, 10-13]. 
  Cells in the central nervous system (CNS) are more vul-
nerable to the toxic effects of RS than those in other organs 
of the body. Brain has a high rate of oxidative metabolic 
activity, high oxygen consumption, low levels of protective 
antioxidant enzymes, a high ratio of membrane surface area 
to cytoplasmic volume, and a neuronal anatomical network 
vulnerable to disruption. The high proportion of readily oxi-
dizable membrane polyunsaturated fatty acids (PUFAs) 
make it more exposed to oxidative stress [7]. Additionally, 
auto-oxidizable neurotransmitters, like dopamine (DA),   
epinephrine and norepinephrine, are present in excess in   
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amounts of hydrogen peroxide (H2O2) and neuronal mito-
chondria can generate superoxide radical (O2
•-) [14]. Fur-
thermore, the presence of potentially toxic amino acids can 
trigger cell proteolysis. Of all the brain regions, the basal 
ganglia may be at particular risk for RS induced damage due 
to their large content of iron [7, 14-16]. 
Antioxidative Defense 
  Human body has a complex defense system of antioxi-
dant enzymes, including superoxide dismutase (SOD), glu-
tathione peroxidase (GpX), and catalase (CAT). These en-
zymes block the initiation of RS chain reactions [17]. The 
non-enzymatic antioxidant components are compounds such 
as glutathione (GSH), vitamin E, vitamin C and -carotene, 
which react with RS and thereby prevent the propagation of 
chain reactions [14, 18, 19]. Oxidative damage of the brain is 
suggested by increased lipid peroxidation products in the 
cerebrospinal fluid and plasma, and reduced membrane PU-
FAs in the brain and red blood cell (RBC) membranes [11]. 
In response to increased RS formation and related membrane 
damage due to lipid peroxidation, the concentration of anti-
oxidant enzymes can rise as a compensatory mechanism. 
Due to their specificity and affinity, in addition to their 
power of self-protection with redox elements in their active 
site and the possibility of amplification, antioxidant enzymes 
are the most important defence against RS [20]. 
Can Peripheral Biomarkers Reflect Status in the CNS? 
  Most measurements of oxidative stress in patients with 
schizophrenia have been made on peripheral tissues. There is 
a lack of information on oxidative processes in cerebrospinal 
fluid and brain. It must be stressed that traces of oxidative 
damage may originate from various sources in the body and 
consequently, such a peripheral indicator may not necessar-
ily reflect the conditions of the oxidative stress parameters in 
the brain [12]. Considering the size of the CNS in compari-
son to the other compartments of the human body, it seems 
reasonable to assume that changes in the levels of enzymes 
inside the brain can influence the enzyme plasma levels [21]. 
  RBCs have often been used for evaluation of oxidative 
stress in patients with schizophrenia. Some illness-related 
abnormalities in RBCs may reflect equivalent abnormalities 
in the neurons, which are hard to examine in vivo [12, 22-
29]. Because of its accessibility, the RBC membrane is 
commonly used as a “window” into the CNS. There are find-
ings that a deficit identified in the RBC membrane is also 
present in the brain of patients with schizophrenia [27-29]. 
Furthermore, alterations in phospholipids metabolism have 
been shown in post-mortem brain of schizophrenia patients. 
31P magnetic resonance spectroscopy allows in vivo evalua-
tion of phospholipids metabolism in the brain. Using this 
noninvasive technique Williamson et al. have demonstrated 
presence of membrane phospholipid abnormalities in schizo-
phrenia, but they could not prove with certainty that these 
abnormalities are specific to schizophrenia [30]. However, in 
a later 31P magnetic resonance study conducted on postmor-
tem brain of patients with schizophrenia, compared to con-
trol there was no significant difference for any subclass of 
phospholipids [31]. 
  Significantly lower levels of GSH, GpX and glutathione 
reductase (GR) were found in the brain of schizophrenia 
patients than in controls, which correlates with the peripheral 
measurements [23-26]. On the other hand, there are studies 
with proton magnetic resonance reporting non significant 
reduction, or even an increase of GSH concentration in the 
brain [32-34]. 
  There are also some suggestions that peripheral nitric 
oxide (NO) metabolites can be used as markers of CNS-
dependent NO changes. Serum total nitrite was increased in 
a group of demyelinating diseases including multiple sclero-
sis, inflammatory neurological diseases and in AIDS patients 
[22]. 
  Besides the theory that oxidative status in CNS influ-
ences the concentration of peripheral biomarkers, it should 
be stressed that also the reverse hypothesis is possible. In a 
study by Aytan et al., it has been demonstrated that periph-
eral oxidative stress can change oxidative status of CNS. In a 
rabbit model high cholesterol feeding caused an increase in 
serum malondialdehyde (MDA), which clearly correlated 
with an increase in protein oxidation parameters in the brain 
[35]. 
  Due to heterogeneity of empirical evidence, currently 
there is no clear support to the value of peripheral biomark-
ers as markers of central oxidative status. It can be concluded 
that the results of studies on CNS (cerebrospinal fluid, post-
mortem or animals) [24, 28, 36-38] show at least correlative 
tendencies with studies assaying biomarkers in erythrocytes, 
plasma or polymorphonuclears. The use of blood compo-
nents in examining RS mediated pathology in schizophrenia 
appears reasonable [39]. Peripheral biomarkers of RS medi-
ated damage have also been suggested to be useful clinically 
in identifying patients with a high risk of developing differ-
ent symptoms of schizophrenia or adverse events of antipsy-
chotic treatment such as extrapyramidal syndrome [40]. 
ABNORMALITIES OF OXIDATIVE STATUS 
Evaluation of Oxidative Status in Schizophrenia 
  Antioxidant enzymes such as SOD, GpX and CAT are 
most commonly measured for quantifying the antioxidative 
defense in schizophrenia, along with vitamin E and C levels 
[41, 42]. While the majority of studies have reported de-
creased antioxidant defense in patients with schizophrenia 
[4, 10, 13, 21, 26, 42-54] there are also some studies where 
the opposite has been reported [12, 55-59]. Several factors, 
such as differences in measuring techniques, differences in 
material tested, exposure to antipsychotic treatment, sam-
pling of patients at different stages of the disease, differences 
in disease etiology and ethnic origin, lifestyle and dietary 
patterns, may be responsible for this discrepancy. Antioxi-
dant enzymes are usually measured in RBCs. According to 
Halliwell et al., antioxidant enzyme levels can drop as a re-
sult of RBC ageing processes. Consequently these measure-
ments reflects only RBC turnover in circulation [60]. Addi-
tionally, MDA tends to have higher levels in summer com-
pared to winter [61]. 
  Antioxidant enzymes levels may be lower at the very 
early stages of psychotic disorder, and may further depend 
on the type of medication, the severity of psychopathology 
or environmental factors [4]. On the other hand, it was sug-
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later in patients on chronic treatment with antipsychotics 
[59]. It was also indicated that haloperidol or other antipsy-
chotics may not have a direct effect on antioxidant enzymes 
and that severity of symptomatology, may influence their 
activities, particularly of SOD and GpX [4, 62]. 
  Taken all together, the majority of studies confirm that 
oxidative stress and oxidative damage is present in schizo-
phrenia, in never-medicated and early stage of disease and in 
treated and chronic stage as well [4, 10, 13, 21, 26, 42-54, 
63]. 
  Considerable attention has been focused on the determi-
nation of biomarkers of lipid peroxidation in schizophrenia. 
PUFAs peroxidation is a chain reaction with a large number 
of intermediates and end point molecules. It can be assayed 
in many ways, such as determination of lipid peroxides, iso-
prostanes, aldehydic end products like MDA and 4-
hydroxynonenal (HNE), and by the determination of volatile 
hydrocarbons. The most frequently assayed marker of lipid 
peroxidation in schizophrenia are thiobarbituric acid related 
substances (TBARS). TBARS have been widely criticized 
for their poor specificity, but they are still acceptable and 
widely used in researches of lipid peroxidation [64]. Results 
of the recent meta-analysis [65] do not lessen belief in this 
parameter, at least within the context of schizophrenia   
research. Measurements of unsaturated aldehydes, such as 
HNE and acrolein, together with isoprostanes, exhaled   
hydrocarbons, and products of enzymatic peroxidation of 
arachidonic acid, such as tromboxane B2 and its metabolite 
11-dehydrotromboxane B2 have been recommended [60, 66, 
67]. 
  Determination of oxidatively modified proteins seems to 
be relevant, considering their importance in cellular function, 
their critical roles in enzyme catalysis, ligand binding and 
signal transduction, and since damaged proteins can contrib-
ute to secondary damage of other molecules. Oxidative 
modification of proteins results in new functional groups and 
can seriously compromise cellular integrity. Protein carbon-
yls are an accepted index of protein oxidation and levels may 
be readily quantified in a variety of ways, including an   
enzyme-linked immunosorbent assay method. They are   
not specific markers of oxidative damage since bound   
aldehydes and glycated proteins are also measured [60, 68]. 
Furthermore, proteins can be damaged by compounds   
other than oxygen species and give products such as para-
hydroxyphenylacetaldehyde, 3-chlorotyrosine, 3,5-dichlo- 
rotyrosine, 3-bromotyrosine and 3-nitrotyrosine. 3-nitro- 
tyrosine in human plasma proteins has been most commonly 
assayed [60]. Oxidative modifications of proteins, measured 
by 3-nitrotyrosine and carbonyl groups, are proven to be 
significantly increased in schizophrenia [69, 70]. 
  Homocysteine has also been suggested as a potentially 
useful biomarker of oxidative stress in schizophrenia. The 
harmful effect of homocysteine arises from generation of RS 
during its catabolism, which could oxidize membrane lipids 
and proteins, including enzymes. In fact, it has been sug-
gested that homocysteine may have a significant influence 
on the development and clinical symptoms of schizophrenia 
[70-72]. 
  Investigation of DNA damage can lead to additional in-
formation as a prospective indicator of carcinogenic and 
mutagenic potential. Elevated levels of 8-hydroxy-2-
deoxyguanosine resulting from DNA damage were deter-
mined in hippocampus of post-mortem schizophrenia pa-
tients [38]. According to Halliwell et al., measurement of 8-
hydroxy-2-deoxyguanosine is the most common method for 
evaluating DNA damage, however, artifactual results arising 
from isolation, preparation and analysis of DNA can easily 
occur [73]. One of the proposed approaches is to measure 
oxidative DNA damage in the intact cell. An assay using 
antibodies has been developed, but it is only semiquantita-
tive. 8-hydroxy-2-deoxyguanosine can also be measured in 
urine, but it is not possible to establish its tissue origin [65, 
73, 74]. 
  Additionally, less specific biomarkers which may reflect 
total oxidant and antioxidant status of plasma (TOS and 
TAS, respectively) as well as oxidative stress index (OSI) 
calculated as ratio of TOS and TAS, have been used to 
evaluate oxidant-antioxidant balance in schizophrenia [51, 
75, 76]. 
  A summary of studies evaluating biochemical alterations 
related to oxidative stress in patients with schizophrenia is 
given in Table 1.
  Other potential biomarkers in schizophrenia, are less   
specific and include plasma arginase manganese blood   
platelets aggregability and apolipoprotein D level [22, 55, 
77-79]. 
Can Different Types of Schizophrenia be Distinguished 
by Measuring Peripheral Signs? 
  Since the distinction between the negative and positive 
symptoms is based mainly on behavioral criteria, and since 
most individuals with schizophrenia exhibit a mixed posi-
tive-negative symptomatology, additional physiological and 
biochemical criteria would be valuable. Available data show 
that potential biomarkers include RBC properties, antioxi-
dant activity, lipid hydrolyzing enzymes such as phospholi-
pase A2, and phospholipid and fatty acid composition. These 
properties not only differ between patients with predomi-
nantly negative and positive symptoms, but many times also 
correlate with the symptom severity [39]. Elevated levels of 
MDA and decreased PUFAs were found in patients with 
negative symptoms, indicating greater oxidative damage in 
this group of patients. Additionally, increased aggregation of 
RBC, O2
•  production and S100 B protein level, but de-
creased activity of GpX were associated with negative symp-
toms [12, 39, 44, 80-82]. On the other hand, positive symp-
toms are correlated with increased level of SOD [44]. 
  Antioxidative status and lipid peroxidation have been 
studied in patients from different schizophrenia subgroups, 
such as disorganized, paranoid and residual schizophrenia. 
The total antioxidant response was found to be higher in the 
paranoid subtype than in disorganized, residual or undiffer-
entiated subtypes [50]. SOD and GpX activities were signifi-
cantly lower in paranoid and residual subtypes than in the 
disorganized subtype and the control group, while CAT ac-
tivity was increased in all groups. The level of SOD in the 
residual group was higher than in the paranoid subtype [83]. 
Treatment refractory patients with schizophrenia suffered 
from greater lipid peroxidation and neuronal damage than 
non-refractory patients [84]. Gamma et al. studied the effects 304    Current Neuropharmacology, 2011, Vol. 9, No. 2 Bo kovi  et al. 
Table 1.  A Summary of Studies Evaluating Biochemical Alterations Related to Oxidative Stress in Patients with Schizophrenia 
Biomarker  Decreased Level  Increased Level 
Antioxidants 
SOD  Akyol et al. 2002, Ben Othmen et al. 2008,  
Dietrich-Muszalska et al. 2005, Li et al. 2006,  
Mukerjee et al. 1996, Pavlovic et al. 2002,  
Ranjekar et al. 2003, Zhang et al. 2006,  
Zhang et al. 2007 
Abdala et al. 1986, Aluntas et al. 2000,  
Dakhale et al. 2004, Kuloglu et al. 2002,  
Michel et al. 2004, Rukmini et al. 2004,  
Surapaneni 2007 
GpX  Abdala et al. 1986, 
*Akyol et al. 2002,  
Aluntas et al. 2000, Ben Othmen et al. 2008,  
Li et al. 2006, 
*Mukerjee et al. 1996,  
Ranjekar et al. 2003, Yao et al. 2006,  
Zhang et al. 2006, Zhang et al. 2007 
Kuloglu et al. 2002, Surapaneni 2007 
CAT  Ben Othmen et al. 2008, Li et al. 2006, 
*Mukerjee  
et al. 1996, 
*Pavlovic et al. 2002, Ranjekar et al. 2003, 
Surapaneni 2007, Zhang et al. 2006, Zhang et al. 2007 
Rukmini et al. 2004 
GSH  Aluntas et al. 2000, Dadheech et al. 2006,  
Pavlovic et al. 2002, Surapaneni 2007,  
Yao et al. 2006, Dietrich-Muszalska et al. 2009 
GR Yao et al. 2006   
Uric acid  Yao et al. 1998   
Vitamin E  Dadheech et al. 2006, Surapaneni 2007   
Vitamin C  Dadheech et al. 2006, Surapaneni 2007   
Total antioxidant status (TAS) 
*Pazvantoglu et al. 2009, Ustundag et al. 2006,  
Virit et al. 2009 
Total oxidant status (TOS) 
*Pazvantoglu et al. 2009, 
*Virit et al. 2009    
TBARS (MDA)  Akyol et al. 2002, Aluntas et al. 2000,  
Ben Othmen et al. 2008, Dadheech et al. 2006,  
Dakhale et al. 2004, Dietrich-Muszalska et al. 2005,  
Khan et al. 2002, Kropp et al. 2008, Kuloglu et al. 2002,  
Pavlovic et al. 2002, Ranjekar et al. 2003,  
Rukmini et al. 2004, Zhang et al. 2006,  
Zhang et al. 2007 
PUFAs  Ranjekar et al. 2003, Khan et al. 2002   
Lipide peroxide   Li  et al. 2006 
3-Nitrotyrosine  Dietrich-Muszalska et al. 2009,  
Dietrich-Muszalska and Olas 2009c. 
Carbonyl groups   Dietrich-Muszalska  et al. 2009 
8-hydroxy-2-deoxyguanosine    Nishioka and Arnold 2004 
Reactive species production 
Xantine oxidase   Akyol  et al. 2002 
Homocysteine   Akanji  et al. 2007, Dietrich-Muszalska et al. 2009 
Superoxide radical release   Sirota  et al. 2003 
NO Akyol et al. 2002, Li et al. 2006, Yilmaz et al. 2007, 
Yanik et al. 2003 
(CAT – catalase, GpX - Glutathione peroxidase, GR - glutathione reductase, GSH – glutathione, MDA – malondialdehyde, NO – nitric oxide, PUFAs - polyunsaturated fatty acids, 
SOD - Superoxide dismutase, TBARS - thiobarbituric acid related substances) 
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of clinical course of DSM-IV schizophrenia subtype on oxi-
dative stress parameters. In comparison to deteoriated group, 
higher level of TBARS was associated with marked symp-
toms [85]. 
  Although there is some empirical evidence that biomark-
ers of oxidative status correlate with symptoms in schizo-
phrenia, there is not a clear correlation that could engage 
biomarkers in process of distinguishing different types of 
schizophrenia. Additional clinical studies are needed to fur-
ther evaluate this theory. 
PATHOPHYSIOLOGY OF OXIDATIVE STRESS 
Dopamine Oxidation 
  The pathology of schizophrenia is suggested to be related 
to oxidative damage [7, 8, 51, 86, 87]. Oxidative stress plays 
a major role in the disease, even though it may not be the 
main cause.
  Different mechanisms of oxidative stress in schizophre-
nia have been postulated. One of the most probable sources 
of RS is DA metabolism [7]. DA has a dihydroquinone 
structure and can be under physiological conditions non-
enzymatically oxidized by molecular oxygen to form hydro-
gen peroxide (H2O2) and the corresponding o-quinone [6, 86, 
88-90]. Non-enzymatic oxidation of catecholamines and 
PUFAs, combined with a deficient antioxidant system in the 
brain, may result in increased lipid peroxidation, which can 
influence the fluidity, integrity and permeability of mem-
branes [87]. 
  Oxidative deamination of DA by monoamine oxidase 
(MAO) can also lead to formation of H2O2 and 3,4-
dihydroxyphenylacetaldehyde [91]. Consequently, both the 
auto-oxidation and the MAO-mediated metabolism of DA 
involve the formation of H2O2, a compound that can easily 
be reduced in the presence of ferrous iron (Fe
2+) to form, 
through the Fenton reaction, hydroxyl radical (OH
• ). Hy-
droxyl radical is considered to be a highly damaging free 
radical for living cells [6, 89-93]. Due to high iron content in 
the brain, DA auto-oxidation is probably the predominant 
source of elevated hydrogen peroxide concentration [89, 90]. 
  Oxidative stress caused by elevated DA levels may en-
hance striatal glutamatergic neurotransmission leading to 
late-onset long-lasting permanent CNS damage [36]. 
  There are also findings that NO may have a role in the 
pathophysiology of schizophrenia. NO is a gaseous neuro-
transmitter which is closely connected to dopaminergic and 
serotonergic neurotransmission. This provides a rationale for 
the involvement of NO and its pathway in schizophrenic 
disorders. Moreover, by interacting with O2
• , NO can pro-
duce peroxynitrite (ONOO
 ). This molecule can act as a neu-
rotoxin by its interaction with the thiol groups on proteins as 
well as by decomposing into the highly reactive hydroxyl 
radical[21, 22, 77, 94-98]. 
Mitochondrial Electron Transport Chain 
  Mitochondrial electron transport chain is an important 
source of RS. Mitochondria convert energy into adenosine 
triphosphate (ATP) by transport of protons across the inner 
mitochondrial membrane. The flow of electrons in the elec-
tron transport chain is a highly regulated process. The last 
step of this process is electron transport to oxygen molecule. 
Normally, oxygen is reduced to produce water. However, 
sometimes oxygen is prematurely and incompletely reduced 
to give the O2
• . This mechanism is well documented   
for Complex I and Complex III [6]. Inhibition of chain   
complexes I, III and IV induces a massive RS production. 
Complex I is the most sensitive and its inactivation by 16% 
results in a significant increase in RS [99]. There is evidence 
of abnormalities in the mitochondrial electron transport chain 
in an animal model and patients with schizophrenia [100-
103]. 
Genetic Factors 
  With the appearance of new technologies and exact phe-
notypic sub-classification, the recognition of genetic bases of 
psychiatric diseases and assessment of disease related altera-
tions is bringing psychiatric research to a new level [104]. A 
genetic contribution to the pathogenesis of schizophrenia has 
been proposed [105-109]. There is evidence that an impaired 
capacity to synthesize GSH due to genetic polymorphism is a 
vulnerability factor for schizophrenia [23, 107]. It has been 
reported that GSH levels are decreased by 27% in the cere-
brospinal fluid and 52% in prefrontal complex of drug-naive 
patients with schizophrenia [25]. Terpstra et al., and Matsu-
zawa et al., found reduction in GSH in brain, but the effect 
did not reach statistical significance [32, 34]. Additionally, 
Wood et al. conducted a study on first episode psychosis 
patients using magnetic resonance spectroscopy technique. 
Medial temporal lobe GSH concentrations were found to be 
22% higher than those in control group. The authors con-
cluded that the reason for the inconsistence with the results 
of the previous studies could be the difference in the stage of 
disease [33]. 
  A positive association between schizophrenia and a func-
tional polymorphism in the gene for manganese SOD has 
been shown in a sample of Japanese schizophrenia patients. 
A significant positive correlation between the total score on 
the Abnormal Involuntary Movements Scale (AIMS) and 
manganese SOD activity was found, which implies a general 
role of the oxidative stress-related genes in the pathogenesis 
of tardive dyskinesia (TD) [109]. Mukherjee et al. found that 
drug-naive first episode patients with schizophrenia have 
SOD activities significantly lower than those in healthy sub-
jects, with no such differences in GpX and CAT activities 
[10]. In another study, in first-episode patients the level of 
SOD was significantly lower, while CAT was significantly 
higher and GpX was unchanged [82]. 
  The molecular mechanisms of the effective antipsychotic 
drugs and recent advances in neural research suggest that 
several genes could be involved in the disorder. Examination 
of the polymorphisms of six genes, D2 and D3 DA receptors, 
serotonin A2 receptor, the brain-derived neurotrophic factor, 
ciliary neurotrophic factor and neurotrophin-3, showed that 
there are significant differences between patients with 
schizophrenia and a control group regarding the D2 receptor 
gene in all patients, and D2 and neurotrophin-3 in female 
patients. The authors conclude that the differences in clinical 
presentation of schizophrenia between genders could have a 
genetic background [105]. 306    Current Neuropharmacology, 2011, Vol. 9, No. 2 Bo kovi  et al. 
Antipsychotic Treatment 
  It was suggested that the typical antipsychotic haloperi-
dol, induces a six-fold increase in the levels of RS generated 
in mitochondria. The pyridinium ion metabolite derived from 
haloperidol might be cytotoxic, and is potentially related to 
drug induced extrapyramidal symptoms and cardiac func-
tional disorder [45, 110-112]. Lipid peroxidation appears to 
be significantly higher after treatment with classical antipsy-
chotics [45]. Moreover, it was found that atypical antipsy-
chotics may improve oxidative status, increasing antioxidant 
levels and decreasing oxidative damage markers such as 
TBARS [82, 113]. Whether this is related directly with the 
effect of drugs on antioxidant enzymes and lipid peroxida-
tion or whether the effect is indirect, through alteration in 
O2
•  and hydroxyl radical formation, remains to be deter-
mined [13, 55]. There appears to be a difference between 
typical antipsychotics, in terms of RS production after long-
term treatment. Atypical antipsychotics show no change in 
lipid peroxidation product levels up to 90 days in treated rats. 
However, further treatment resulted in a significant increase 
in lipid peroxidation in the treatment with clozapine, ziprasi-
done and risperidone, but not with olanzapine [114]. Addi-
tionally, clozapine was found to induce oxidative stress and 
pro-apoptotic gene expression in neutrophils of patients with 
schizophrenia [79, 115]. Some authors indicate that the 
changes in the activity of antioxidant enzymes and levels of 
biomarkers of oxidative damage, studied in patients with 
schizophrenia, are independent of antipsychotic treatment 
and may reflect the pathophysiological process of the dis-
ease. No effects of duration of the disease, gender or dose of 
chlorpromazine equivalents were observed [21]. 
THERAPEUTIC STRATEGIES FOR THE PRE- 
VENTION AND AMELIORATION OF OXIDATIVE   
DAMAGE 
  The endogenous antioxidant defense systems are not al-
ways entirely successful. The harmful effect in schizophrenia 
originating from RS could potentially be relieved by inacti-
vation of RS by nutritional intake of antioxidants and essen-
tial fatty acids [11]. This is supported by an experiment on 
animal model. In rats fed with PUFAs brain SOD activity 
increased [37]. 
  Vitamin E is a potent lipid soluble antioxidant that can 
stop the spread of the chain reaction in the lipid part of the 
cell membrane [18]. The concentration of vitamin E in pe-
ripheral nerves correlates with its concentration in plasma 
and depends on the dietary intake. Additionally, a deficit of 
vitamin E can attenuate the antioxidative defense [19]. Cur-
rently, there is not enough evidence that supplementation 
with vitamin E improves symptoms of neuroleptic-induced 
TD [116]. 
  Vitamin C is a water soluble antioxidant that scavenges 
RS. It can inhibit peroxidation of the membrane phospholip-
ids, and can also improve regeneration of vitamin E. There is 
a 10-times higher concentration of vitamin C in the brain 
than in serum. In its oxidized form, vitamin C can cross the 
brain blood barrier, presumably via glucose transporter 
GLUT1, and is retained in the brain tissue. It is hypothesized 
that increased dietary intake of vitamin C influences its con-
centration in the brain [19]. 
  There are a few molecules with antioxidant activity, such 
as melatonin, -lipoic acid and coenzyme Q10, that can pass 
the blood brain barrier and ameliorate oxidative status in 
rats. Their use in neurodegenerative diseases, evaluation of 
their antioxidant activity and possible effects on other sys-
tems need to be further characterized [19]. 
  In studies on patients with schizophrenia, the most com-
monly used antioxidants were vitamins E and C. Vitamin E 
is a lipid soluble antioxidant able to prevent the oxidative 
damage. Nevertheless, it has a small potential in preventing 
oxidative damage to cytosolic proteins, mitochondria, and 
nucleus, where most of the RS are produced. Therefore, it is 
reasonable to add vitamin C, a water soluble antioxidant. The 
adjunctive use of vitamins C and E in schizophrenia requires 
caution since a high dietary intake will result in pro-oxidant 
rather than antioxidant actions [117]. In addition, supplemen-
tation with other antioxidants such as N-Acetyl Cysteine 
[118-121], rutin [122], Ginkgo biloba [54, 123-126], mela-
tonin [127-129], hydroxytyrosol [130], caffeic acid phenethyl 
ester [131], resveratrol and quercetin [132] and lycopene 
[133, 134] has been suggested. 
  Among herbal supplemental antioxidative therapies used 
is schizophrenia, Ginkgo biloba was most widely studied. 
However, many studies were underpowered and poorly re-
ported. Additionally, there is still some uncertainty which 
chemical compound was responsible for therapeutic effects. 
Two recently published meta-analyses [123, 126] demon-
strated that treatment with Ginkgo biloba resulted in moder-
ate improvement in total and negative symptoms of schizo-
phrenia. 
  There is strong evidence that GSH concentration is de-
creased in cerebrospinal fluid, prefrontal cortex and postmor-
tem caudate of patients with schizophrenia [23, 25, 33, 34, 
107, 120]. Since cysteine is the rate-limiting precursor for 
GSH synthesis, it was proposed that treatment with N-acetyl 
cysteine could restore GSH levels [121]. A recent random-
ized multicenter study involving 84 subjects demonstrated a 
positive effect of N-acetyl cysteine on total, general and 
negative component of PANSS and revealed an improve-
ment of CGI-severity and CGI-improvement scales. Addi-
tionally, treatment with N-acetyl cysteine was associated 
with an amelioration of akathisia. No significant effect on 
PANSS positive subscale was observed [118]. Bulut et al.
reported a case of poorly responsive patient with schizophre-
nia, with significant improvement after supplementation with 
N-acetyl cysteine [119]. A growing body of evidence sug-
gests potential effectiveness of N-acetyl cysteine in schizo-
phrenia, which has to be further confirmed. 
  Since nutritional intake of essential PUFAs affects the 
fatty acid composition of the neuronal cell membrane phos-
pholipids, the addition of PUFAs, particularly omega-3 and 
omega-6, could be a solution for the recovery of damaged 
membrane structures [37, 135-137]. 
  The results of the use of vitamin E and omega-3 or 6- 
PUFAs are presented in Tables 2 and 3. Only randomized, 
double-blind clinical trials were selected for evaluating the 
influence of supplemental treatment on clinical symptoms in 
schizophrenia. All accessible studies with vitamin C treat-
ment and treatment with various combinations of antioxi-
dants and PUFAs are presented. Oxidative Stress in Schizophrenia  Current Neuropharmacology, 2011, Vol. 9, No. 2    307
  To evaluate the effect of vitamin E treatment in patients 
with schizophrenia we performed a meta-analysis. Selection 
criteria for inclusion of the study were study duration (at 
least 4 weeks) and adequately reported treatment effect (dif-
ference in Abnormal Involuntary Movement Scale (AIMS) 
score compared to baseline value). Of the studies reported in 
Table 2 seven studies met the inclusion criteria [138-144]. 
From the extracted data weighted mean difference (WMD) 
with 95% confidence interval (95% CI) was calculated using 
Review Manager 4.2 (The Cochrane Collaboration, Oxford, 
UK). Random effect model was applied due to heterogeneity 
of the results of various studies. WMD of the improvement 
on AIMS was 1.92 (95% CI 0.60 to 3.24) suggesting signifi-
cant treatment effect. 
Table  2.  Effect of Supplemental Treatment (Vitamin E and C) in Patients with Schizophrenia, Observed in Double-Blind   
Randomized Studies. Reports for Vitamin E were Included According to Data from Cochrane Library Data Base (Soares 
and McGrath, 2001) 
Vitamin E Studies  Study Duration, Number of Patients  Intervention  Outcome 
Adler 1993   12 weeks, N=28  Vitamin E 1600 IU/day  Significant reduction of AIMS score in favor of 
vitamin E 
Adler 1999   2 years, N=158   Vitamin E 1600 IU/day   No significant reduction of AIMS and BPRS  
Dabiri 1994   12 weeks, N=12  Vitamin E 1200 IU/day  Significant reduction of AIMS 
Elkashef 1990   4 weeks, N=10  Vitamin E 1200 IU/day  Significant reduction of AIMS 
Lam 1994   6 weeks, N=16  Vitamin E 1200 IU/day  No significant reduction of AIMS  
Lohr 1996   8 weeks, N=55  Vitamin E 1600 IU/day  Significant reduction of AIMS and not of BPRS 
Sajjad 1998  7 months, N=20  Vitamin E 600 IU/day  Significant reduction of AIMS score 
Vitamin C studies 
Nikolaus 2002 
*(Nicolaus et al., 2002)
2 years , N=6  Vitamin C 200 mg/day and 
vitamin E 1.8 mg/day  
Significant reduction in dyskinetic movements 
total score 
Dakhale 2005 
(Dakhale et al. 2005)
 8 weeks , N=40  Vitamin C 500 mg/day   Significant reduction in MDA and BPRS 
* Prospective open study. 
(N- number of subjects, AIMS- Abnormal Involuntary Movement Syndrome Scale, BPRS - Brief Psychiatric Rating Scale, TDRS - Tardive Dyskinesia Rating Scale, MDA - 
Malondialdehyde). 
Table 3.  Effect of Supplemental Treatment with Polyunsaturated Fatty Acids or Combination of Antioxidants and Polyunsatu- 
rated Fatty in Patients with Schizophrenia, Observed in Double Blind Randomized Studies. Reports for Fatty Acid   
Supplemental Therapy were Included According to Data from Cochrane Library Data Base (Joy et al., 2007) 
Fatty Acids Studies  Method  Intervention  Outcome 
Emsley 2006   12 weeks, N=77  E-EPA 2g/day  No significant difference in ESRS 
Emsley 2002  12 weeks, N=40  E-EPA 3g/day  Significant reduction in PANSS scores 
Fenton 2001  16 weeks, N=90  E-EPA 500 mg/day and vitamin E  No significant change in PANSS, M-ADRS, 
AIMS, S-ARS, CGI 
Peet 2001  12 weeks, N=55  EPA 2g, DHA 2g 
Comparative study 
Significant reduction in PANSS scores. EPA  
is superior to DHA 
Peet 2002  12 weeks, N=55  EPA 1g/day, EPA 2g/day, EPA 3g/day, 
EPA 4g/day. Comparative study 
Significant reduction in PANSS scores, the  
biggest for those who had EPA 2g/day 
Vitamins E and C and fatty acids 
Arvindakshan 2003 *  4 months, N=33  EPA/DHA 180:120 mg 
Vitamin E:C 400 IU/bid: 500mg/bid 
Significant reduction of PANSS and BPRS  
and increase of QOL 
Sivrioglu 2007 *  4 months, N=17  EPA/DHA 180:120 mg 
Vitamin E:C 400 IU/bid: 1000mg/day 
Significant reduction of BPRS, SANS, S-ARS 
and BARS. 
* Prospective open study.  
(N- number of subjects, ESRS -Extrapyramidal Symptom Rating Scale, AIMS - Abnormal Involuntary Movement Syndrome scale, BPRS - Brief Psychiatric Rating Scale, PANSS - 
Positive and Negative Syndrome Scale, SANS - Scale for Assessment of Negative Symptoms, BARS - Barnes Akathisia Rating Scale, M-ADRS - Montgomery-Asberg Depression 
Rating Scale, S-ARS - Simpson-Angus Rating Scale, CGI - Clinical Global Impression scale, QOL - Henrich’s Quality of Life scale, EPA - Eicosapentaenoic Acid, E-EPA -Ethyl 
eicosapentaenoic acid, DHA - Docosahexaenoic acid).308    Current Neuropharmacology, 2011, Vol. 9, No. 2 Bo kovi  et al. 
  We find it interesting that two different studies of Adler 
et al., conducted with the same dose of vitamin E, had op-
posing results [138, 139]. The former study was conducted 
with a much smaller number of patients, 28 in comparison to 
158 in the later study. Furthermore, the second study lasted 
much longer, 2 years in comparison to 12 weeks in the first 
study. In spite of this, the second study showed no signifi-
cant influence of vitamin E on involuntary movement symp-
toms, as was observed in the first study. This suggests that 
there must be some difference in the chosen patient popula-
tion. The authors themselves point out that when the first 
study was conducted, in 1993, therapy of schizophrenia was 
based mostly on the use of the classical antipsychotics while 
in 1999 atypical antipsychotics appeared in the prescribing 
patterns. Therefore, patients included in the later study were 
treated with classical or with atypical antipsychotics. Taking 
into account that there is considerable difference in the DA 
receptor blocking, the induction of RS production and in TD 
appearance between these two classes of antipsychotics, vi-
tamin E would not be expected to have the same effect on 
symptoms improvement. The damaging potential and the 
symptoms observed differ considerably. Atypical antipsy-
chotics induce much less TD in patients with schizophrenia. 
In spite of this, the Texas Medication Algorithm Project pro-
poses that there is no reason to prefer atypical over classical 
antipsychotics in chronic schizophrenia, although opinion 
about this recommendation appears to be divided [145]. 
Considering the fact that classical antipsychotics are still 
used in therapy of schizophrenia, further studies evaluating 
supplementation with vitamin E are recommended. Both 
studies by Adler et al. included very few female patients, 
making it a highly unrepresentative patient sample. 
  As far as vitamin C is concerned, there is very little data. 
Available studies with vitamin C treatment and treatment 
with combinations of vitamin C and vitamin E show a sig-
nificant improvement in BPRS score and reduction in dyski-
netic movement total score [117, 146]. 
  From the review of the effects of supplementation with 
PUFAs in schizophrenia, it can be concluded that they might 
improve mental state and movement disorder symptoms. 
This is mostly associated with omega-3 PUFAs, since there 
is only limited information on supplementation with omega-
6 PUFAs [147]. Meta-analysis of 5 eligible studies reported 
in Table 3 [148-152] revealed insignificant improvement on 
PANSS score (WMD 2.85 95% CI -1.20 to 6.89). There are 
still too few data on the role of essential fatty acid supple-
mentation in the treatment of patients with schizophrenia, 
and larger, well designed clinical studies need to be   
conducted. 
  Despite the suggestion that combined therapy with anti-
oxidants and PUFAs is potentially more effective than 
monotherapy in patients with schizophrenia [3], only two 
studies with combined treatment were found [49, 153]. Posi-
tive results were observed in both of the studies which, how-
ever, were not controlled. 
CONCLUSIONS 
  There is a growing body of evidence that oxidative stress 
is involved in the pathology of schizophrenia. Mechanisms 
involved include genetic susceptibility, catecholamine   
metabolism, and critical surroundings in the CNS (glutamate, 
iron, highly oxidizable fatty acids). Antipsychotic treatment, 
especially treatment with classical antipsychotics, also con-
tributes to oxidative stress promotion. 
  Oxidative stress in schizophrenia can be evaluated with a 
wide spectrum of biomarkers. However, specific biomarkers 
based on a non-invasive sampling method, stable in biologi-
cal materials, and easy to measure, has still to be discovered. 
It is suggested that measurements in blood can reflect oxida-
tive status in CNS and can be clinically useful in identifying 
patients at high risk of developing adverse effects. However, 
this needs further confirmation. There are indications that 
different types of schizophrenia, and positive and negative 
symptoms, can be distinguished by the levels of biomarkers. 
This would be of great help in the diagnosis of schizophrenia 
and in predicting the course of disease. Attempts to amelio-
rate oxidative damage and therapeutically induced ex-
trapyramidal syndrome are of considerable importance. The 
use of antioxidants and PUFAs in the treatment of schizo-
phrenia has yielded some positive results, but still remains 
experimental. There is a need for larger, well designed clini-
cal studies. Further studies need to be placebo-controlled 
with larger numbers of patients on standardized antipsy-
chotic therapy and duration of disease. Since PUFAs admin-
istered together with antioxidant vitamins are potentially 
effective low cost supplemental treatment with few side ef-
fects, such therapy may become a significant advance in the 
treatment of schizophrenia. 
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